Equity Profile

VCYT

Veracyte, Inc.

Health CareBiotechnology$4.6B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through genomic diagnostics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.52

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for validating the company's market position and operational effectiveness.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VCYT Q2-2026 Earnings Preview

Context

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through genomic diagnostics. Operating in the health care sector, Veracyte develops tests that help physicians make more informed decisions, particularly in cancer diagnostics and other diseases, which is increasingly important in personalized medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1-2026, Veracyte reported an EPS of $0.52, significantly beating expectations by over 126%. The stock reacted negatively the following day, indicating potential market skepticism despite the strong earnings.

Management Promises & Guidance

Continued focus on expanding their diagnostic offerings.
Commitment to enhancing partnerships within the health care sector.
Plans to invest in research and development to drive innovation.

Expectations

Wall Street Expectations

Overall, the market anticipates another strong performance from Veracyte, especially given its track record of beating earnings expectations. However, investor sentiment may be cautious due to the recent stock price reaction despite positive earnings.

Bull Case

If Veracyte continues its trend of exceeding EPS expectations, it could bolster investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the recent market reactions.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.52

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, growth in revenue is crucial for validating the company's market position and operational effectiveness.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth can Veracyte report this quarter?

Revenue growth will be a critical indicator of the company's market performance and ability to capitalize on its diagnostic offerings.

Will management provide guidance on future earnings or product launches?

Guidance on future earnings or new products can significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Veracyte's ability to leverage its recent product innovations, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

Veracyte has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a significant move, suggesting that traders expect volatility that could favor a positive outcome.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to maintain its earnings momentum against potential operational challenges.

Bull Confirmed If

An EPS of $0.55 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.50 could signal potential issues with growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±17.32%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±17.3% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

80.2%

Calls (4K)P/C Ratio: 0.00Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations, history suggests the stock could rise by about 0.09% on the first day, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see minimal movement as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline, with an average drop of 1.43% following the last earnings report.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships.
2Management's commentary on revenue growth and market demand.
3Insights into operational challenges or competitive pressures.
4Guidance on future earnings and strategic initiatives.
5Details on customer adoption rates for existing products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through genomic diagnostics....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.52

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for validating the company's market position and operational effectiveness.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

VCYT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding their diagnostic offerings.
Commitment to enhancing partnerships within the health care sector.
Plans to invest in research and development to drive innovation.

Expectations

Wall Street Expectations

Bull Case

If Veracyte continues its trend of exceeding EPS expectations, it could bolster investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price, especially given the recent market reactions.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.52

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, growth in revenue is crucial for validating the company's market position and operational effectiveness.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth can Veracyte report this quarter?

Revenue growth will be a critical indicator of the company's market performance and ability to capitalize on its diagnostic offerings.

Will management provide guidance on future earnings or product launches?

Guidance on future earnings or new products can significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Veracyte's ability to leverage its recent product innovations, which could lead to stronger-than-expected revenue growth this quarter.

Supporting Evidence

Veracyte has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a significant move, suggesting that traders expect volatility that could favor a positive outcome.

Key Risk

If revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's ability to maintain its earnings momentum against potential operational challenges.

Bull Confirmed If

An EPS of $0.55 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.50 could signal potential issues with growth and profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±17.32%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±17.3% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

80.2%

Calls (4K)P/C Ratio: 0.00Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations, history suggests the stock could rise by about 0.09% on the first day, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see minimal movement as investors digest the commentary.

Miss

If the company misses expectations, history suggests a potential decline, with an average drop of 1.43% following the last earnings report.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships.
2Management's commentary on revenue growth and market demand.
3Insights into operational challenges or competitive pressures.
4Guidance on future earnings and strategic initiatives.
5Details on customer adoption rates for existing products.